Shenzhou Cell (688520.SH) subsidiary Shenzhou Cell Engineering obtains drug registration certificate

Shenzhou Cell (688520.SH) announced that its holding subsidiary Shenzhou Cell Engineering Co., Ltd. (referred to as "Shenzhou Cell Engineering") recently received the "Drug Registration Certificate" issued by the National Medical Products Administration. The registration application for the combined use of Fennori monoclonal antibody injection (trade name: Anyuping) and Bevacizumab monoclonal antibody injection (trade name: Anbeizhu) for the treatment of inoperable or metastatic hepatocellular carcinoma that has not previously received systemic treatment has been approved. This is the second indication for which the Fennori monoclonal antibody injection has been approved for marketing.